Press

Fount Therapeutics, LLC is a sustainable drug discovery enterprise with a proven team of R & D talent that has created multiple launched medicines.

06.12.2018

Fount Therapeutics, LLC is a sustainable drug discovery enterprise with a proven team of R & D talent that has created multiple launched medicines. Fount is maturing three newco subsidiaries: Kinnate Biopharma, Inc. (Oncology), Immanate Therapeutics, Inc. (Immunology & Immuno-Oncology), and Audere Medicines, Inc. (theme undisclosed). Continue

Eyenovia completes IPO - Raises $27.5 mm

01.25.2018

Continue

MDCO sells ID franchise to Melinta

11.29.2017

Continue

GI enters into collaboration with AstraZeneca to evaluate Tagrisso in combination with G1 CDK 4/6 inhibitor GIT 38

11.28.2017

Continue

G1 Therapeutics Announces Pricing of Initial Public Offering

05.17.2017

Continue

G1 Therapeutics Announces Launch of Initial Public Offering

05.08.2017

Continue

G1 Therapeutics files S1

04.13.2017

Continue

Adidas Unveils Industry's First Application of Digital Light Synthesis with FutureCraft 4D (created by Carbon)

04.07.2017

Continue

MediKidz now Jumo Health

04.01.2017

Continue

G1 Therapeutics Announces Expansion of Development Programs

01.10.2017

G1 Therapeutics announced today the expansion of its pipeline of novel cancer therapies with initiation of three development programs in breast cancer. G1 is enrolling a Phase 2 study of its intravenous CDK4/6 inhibitor trilaciclib for the treatment of triple-negative breast cancer (TNBC), and a Phase 1b/2a study of its oral CDK4/6 inhibitor G1T38 for the treatment of ER+, HER2-... Continue